Author:
Sutanto Edwin,Pava Zuleima,Echeverry Diego F.,Lopera-Mesa Tatiana M.,Montenegro Lidia Madeline,Yasnot-Acosta Maria F.,Benavente Ernest Diez,Pearson Richard D.,Herrera Sócrates,Arévalo-Herrera Myriam,Trimarsanto Hidayat,Rumaseb Angela,Noviyanti Rintis,Kwiatkowski Dominic P.,Price Ric N.,Auburn Sarah
Abstract
AbstractColombia aims to eliminate malaria by 2030 but remains one of the highest burden countries in the Americas. Plasmodium vivax contributes half of all malaria cases, with its control challenged by relapsing parasitaemia, drug resistance and cross-border spread. Using 64 Colombian P. vivax genomes collected between 2013 and 2017, we explored diversity and selection in two major foci of transmission: Chocó and Córdoba. Open-access data from other countries were used for comparative assessment of drug resistance candidates and to assess cross-border spread. Across Colombia, polyclonal infections were infrequent (12%), and infection connectivity was relatively high (median IBD = 5%), consistent with low endemicity. Chocó exhibited a higher frequency of polyclonal infections (23%) than Córdoba (7%), although the difference was not significant (P = 0.300). Most Colombian infections carried double pvdhfr (95%) and single pvdhps (71%) mutants, but other drug resistance mutations were less prevalent (< 10%). There was no evidence of selection at the pvaat1 gene, whose P. falciparum orthologue has recently been implicated in chloroquine resistance. Global population comparisons identified other putative adaptations. Within the Americas, low-level connectivity was observed between Colombia and Peru, highlighting potential for cross-border spread. Our findings demonstrate the potential of molecular data to inform on infection spread and adaptation.
Funder
Colciencias Colombia
Medical Research Council
Wellcome Trust
Bill and Melinda Gates Foundation
National Health and Medical Research Council of Australia
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. WHO. World Malaria Report 2022. World Health Organization; Geneva 2022. (2022).
2. Colombia Instituto National de Salud Boletín Epidemiológico website. https://www.ins.gov.co/buscador-eventos/Paginas/Vista-Boletin-Epidemilogico.aspx. Accessed 30 June 2023.
3. Mesa-Echeverry, E., Niebles-Bolivar, M. & Tobon-Castano, A. Chloroquine-primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated plasmodium vivax malaria in a Colombian Pacific Region. Am. J. Trop. Med. Hyg. 100, 72–77. https://doi.org/10.4269/ajtmh.18-0655 (2019).
4. Castro-Cavadia, C. J. & Carmona-Fonseca, J. Assessment of the efficacy and safety of chloroquine monotherapy for the treatment of acute uncomplicated gestational malaria caused by P. Vivax, Cordoba, Colombia, 2015–2017. Rev. Colomb. Obstet. Ginecol. 71, 21–33. https://doi.org/10.1897/rcog.3370 (2020).
5. Luo, Z., Sullivan, S. A. & Carlton, J. M. The biology of Plasmodium vivax explored through genomics. Ann N Y Acad Sci 1342, 53–61. https://doi.org/10.1111/nyas.12708 (2015).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献